Plaque, Amyloid: Clinical Trials

47 trials for Plaque, Amyloid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28 completed, 5 recruiting, 5 terminated, 4 unknown. 47 Phase 2, 6 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 247Completed 28, Recruiting 5, Terminated 5, Unknown 4, Not yet recruiting 3, Active not recruiting 1, Suspended 1
Phase 16Completed 3, Recruiting 1, Terminated 1, Unknown 1
Phase 33Completed 1, Recruiting 1, Terminated 1

Follow Plaque, Amyloid: new trials by email Literature Review of Plaque, Amyloid trials Research Report on Plaque, Amyloid

Trials (filtered) newest first · largest first

All 47 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease
AV-1959R, Placebo - Preclinical Alzheimer's Disease, Alzheimer Disease
Phase 2Not yet recruitingInstitute for Molecular Medicine1602027-10-012026-10-21
Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis
IRX4204, Placebo - Psoriasis, Plaque Type Psorisis
Phase 2SuspendedIo Therapeutics202027-03-012026-11-12
A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease
GAL-101 Salt, Placebo - Mild to Moderate Alzheimer's Disease
Phase 2Not yet recruitingGalimedix Therapeutics Inc1002027-02-282026-08-27
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment
Lenalidomide 10 mg - Cognitive Impairment, Mild, Cognitive Dysfunction
Phase 2Not yet recruitingSt. Joseph's Hospital and Medical Center, Phoenix452025-06-012025-05-18
A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.
Lemborexant 10 MG, Placebo - Insomnia
Phase 2RecruitingWoolcock Institute of Medical Research202025-05-132026-09-18
Role of Kefir Mouth Wash in Oral Health Status Amelioration
Kefir Mouth Wash, Chlorhexidine 0,12%Biofresh Mouthwash - Plaque Induced Gingivitis, Halitosis
Phase 2 / Phase 3RecruitingAl-Mustansiriyah University602025-04-062025-04-24
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
GAL-101, Placebo - Geographic Atrophy of the Macula
Phase 2RecruitingGalimedix Therapeutics Inc1102025-01-102026-11-10
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Darovasertib - Uveal Melanoma
Phase 2Active not recruitingIDEAYA Biosciences1602023-07-032026-03-16
Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant
Xylitol, Placebo - Allogeneic Stem Cell Transplantation
Phase 2TerminatedChildren's Hospital Medical Center, Cincinnati2562023-04-042026-11-02
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a - Amyloid Plaque, Beta-Amyloid
Phase 1 / Phase 2RecruitingAC Immune SA3042022-06-212026-07-10
Sleep Trial to Prevent Alzheimer's Disease
Suvorexant 20 mg, Placebo - Sleep, Alzheimer Disease
Phase 2RecruitingUniversity of Minnesota1202022-05-252026-07-13
High Dose Risankizumab for Psoriasis
risankizumab - Psoriasis
Phase 2CompletedOregon Medical Research Center202022-03-012025-10-24
Clinical Study of Toothpaste Containing Zinc Lactate as Compared to Colgate Cavity Protection Toothpaste.
Meridol, Colgate Cavity Protection - Gingivitis, Plaque
Phase 2CompletedColgate Palmolive922022-01-182024-08-21
Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease
Citalopram 20mg, Placebo - Parkinson Disease
Phase 2CompletedUniversity of Michigan582021-04-012026-03-16
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
Lenalidomide 10 mg, Placebo - Cognitive Impairment, Mild, Cognitive Dysfunction
Phase 2CompletedSt. Joseph's Hospital and Medical Center, Phoenix152020-07-222026-06-10
Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer's Disease
F-18-AV45 - Alzheimer's Disease
Phase 2UnknownChang Gung Memorial Hospital3002019-03-282019-11-22
The Influence of Vascular Burden, Amyloid Plaque and Tau Protein in Patients With Vascular Cognitive Impairment and Dementia With Tauopathy
PMPBB3, AV45 - Vascular Cognitive Impairment, Alzheimer's Disease, Fronto-temporal Dementia
Phase 2UnknownChang Gung Memorial Hospital2202018-09-212023-05-01
Metagenomic and Metatranscriptomic Analysis of Clinical Plaque Samples
Colgate Maximum Cavity Protection plus Sugar Acid Neutralizer, Colgate Cavity Protection - Plaque
Phase 2CompletedColgate Palmolive342017-10-062021-12-01
Blood Brain Barrier Opening in Alzheimer' Disease
SONOCLOUD® - Alzheimer Disease
Phase 1 / Phase 2CompletedAssistance Publique - Hôpitaux de Paris102017-06-262022-04-12
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
Belumosudil, Placebo - Chronic Plaque Psoriasis
Phase 2CompletedKadmon Corporation, LLC1102016-09-142022-03-16

Showing 20 of 47. Sign in to see all of them.

Narrower conditions

Alzheimer Disease (17)  ·  Psoriasis (9)  ·  Dementia (4)  ·  Gingivitis (4)  ·  Lymphoma, Follicular (4)  ·  Bronchiolitis Obliterans Syndrome (3)  ·  Cognitive Dysfunction (3)  ·  Pick Disease of the Brain (3)  ·  Skin Diseases (3)  ·  Atherosclerosis (2)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Coronary Artery Disease (2)  ·  Down Syndrome (2)

Broader conditions

Pathological Conditions, Anatomical (47)  ·  Pathological Conditions, Signs and Symptoms (47)  ·  Nervous System Diseases (22)  ·  Brain Diseases (19)  ·  Central Nervous System Diseases (19)  ·  Neurocognitive Disorders (19)  ·  Neurodegenerative Diseases (19)  ·  Mental Disorders (18)  ·  Tauopathies (17)  ·  Dementia (15)  ·  Skin and Connective Tissue Diseases (10)  ·  Skin Diseases, Papulosquamous (8)  ·  Skin Diseases (7)  ·  Stomatognathic Diseases (7)  ·  Pathologic Processes (6)

Interventions

4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (2)  ·  Lenalidomide (2)  ·  Rosuvastatin Calcium (2)  ·  Sugars (2)  ·  florbetapir (2)  ·  secukinumab (2)  ·  7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1)  ·  AGN 194204 (1)  ·  Capsules (1)  ·  Carnitine (1)  ·  Cellulose (1)  ·  Citalopram (1)  ·  Diffusion Tensor Imaging (1)  ·  Genetic Testing (1)  ·  IRX4204 (1)

Sponsors

Novartis Pharmaceuticals (3)  ·  Chang Gung Memorial Hospital (2)  ·  Colgate Palmolive (2)  ·  Eli Lilly and Company (2)  ·  Galimedix Therapeutics Inc (2)  ·  Instituto Grifols, S.A. (2)  ·  Lantheus Biosciences Ltd. (2)  ·  St. Joseph's Hospital and Medical Center, Phoenix (2)  ·  AC Immune SA (1)  ·  Al-Mustansiriyah University (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Brigham and Women's Hospital (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Dr. Amer Johri (1)  ·  Emory University (1)

Countries

United States (28)  ·  Germany (6)  ·  Canada (5)  ·  Australia (3)  ·  France (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  Denmark (2)  ·  Israel (2)  ·  Italy (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Taiwan (2)  ·  Armenia (1)  ·  Belgium (1)

Top investigators

Amer M Johri, MD (1)  ·  Andrew Stephens, PhD (1)  ·  Anke Gauliard, MD (1)  ·  Annapoorna Kini, MD (1)  ·  Antonio Paez (1)  ·  Benjamin D Ehst, MD, PhD (1)  ·  Boris Decourt, PhD (1)  ·  Brendan Lucey, MD (1)  ·  Brendon Yee, MBChB, FRACP, FCCP, PhD (1)  ·  Camilla Hoyos, MPH, PhD (1)  ·  Christopher Dandoy, MD, MSc (1)

Results publications

PMID 33773598, PMID 21481640, PMID 22455413, PMID 22473769, PMID 23686372, PMID 24152824, PMID 25242558, PMID 25669746, PMID 25693783, PMID 27989886, PMID 3425152, PMID 34815790, PMID 35061234, PMID 35260178, PMID 35342978, PMID 35366920, PMID 35867135, PMID 36440097, PMID 3793432, PMID 38489186, PMID 38896380, PMID 39466933, PMID 39910536, PMID 40640892

NIH funding

1UG3DE030401-01 (1), 2016 (1), K01AG047279 (1), R01AG049752 (1), R01AG059008 (1), R01AG065246 (1)